Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Mar 31;16(7):1376.
doi: 10.3390/cancers16071376.

Posterior and Para-Aortic (D2plus) Lymphadenectomy after Neoadjuvant/Conversion Therapy for Locally Advanced/Oligometastatic Gastric Cancer

Affiliations

Posterior and Para-Aortic (D2plus) Lymphadenectomy after Neoadjuvant/Conversion Therapy for Locally Advanced/Oligometastatic Gastric Cancer

Daniele Marrelli et al. Cancers (Basel). .

Abstract

Super-extended (D2plus) lymphadenectomy after chemotherapy has been reported in only a few studies. This retrospective study evaluates survival outcomes in a Western cohort of locally advanced or oligometastatic gastric cancer patients who underwent D2plus lymphadenectomy after neoadjuvant chemotherapy. A total of 97 patients treated between 2010 and 2022 were included. Of these, 62 had clinical stage II/III disease, and 35 had stage IV disease. Most patients (65%) received preoperative DOC/FLOT chemotherapy. The mean number of lymph nodes harvested was 39. Pathological positive nodes in the posterior/para-aortic stations occurred in 17 (17.5%) patients. Lymphovascular invasion, ypN stage, clinical stage, and perineural invasion were predictive factors for positive posterior/para-aortic nodes. Postoperative complications occurred in 21 patients, whereas severe complications (grade III or more) occurred in 9 cases (9.3%). Mortality rate was 1%. Median overall survival (OS) was 59 months (95% CI: 13-106), with a five-year survival rate of 49 ± 6%; the five-year OS after R0 surgery was 60 ± 7%. In patients with positive posterior/para-aortic nodes, the median OS was 15 months (95% CI: 13-18). D2plus lymphadenectomy after chemotherapy for locally advanced or oligometastatic gastric cancer is feasible and associated with low morbidity/mortality rates. The incidence of pathological metastases in posterior/para-aortic nodes is not negligible even after systemic chemotherapy, with poor long-term survival.

Keywords: D2plus lymphadenectomy; conversion; gastric cancer; neoadjuvant; para-aortic nodes; posterior nodes; survival.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Number of lymph nodes removed in the study population divided by first-, second-, and third-level stations.
Figure 2
Figure 2
Survival curves: (a) overall survival based on posterior/para-aortic lymph node involvement; (b) overall survival based on ypN stage compared with positive posterior/para-aortic nodes at pathological evaluation.

References

    1. De Manzoni G., Marrelli D., Baiocchi G.L., Morgagni P., Saragoni L., Degiuli M., Donini A., Fumagalli U., Mazzei M.A., Pacelli F., et al. The Italian Research Group for Gastric Cancer (GIRCG) Guidelines for Gastric Cancer Staging and Treatment: 2015. Gastric Cancer. 2017;20:20–30. doi: 10.1007/s10120-016-0615-3. - DOI - PubMed
    1. Japanese Gastric Cancer Association . Japanese Gastric Cancer Treatment Guidelines 2021. 6th ed. Volume 26. Springer; Berlin/Heidelberg, Germany: 2023. pp. 1–25. In Gastric Cancer. - DOI - PMC - PubMed
    1. Lordick F., Carneiro F., Cascinu S., Fleitas T., Haustermans K., Piessen G., Vogel A., Smyth E.C. Gastric Cancer: ESMO Clinical Practice Guideline for Diagnosis, Treatment and Follow-Up. Ann. Oncol. 2022;33:1005–1020. doi: 10.1016/j.annonc.2022.07.004. - DOI - PubMed
    1. Sasako M., Sano T., Yamamoto S., Kurokawa Y., Nashimoto A., Kurita A., Hiratsuka M., Tsujinaka T., Kinoshita T., Arai K., et al. D2 Lymphadenectomy Alone or with Para-Aortic Nodal Dissection for Gastric Cancer. N. Engl. J. Med. 2008;359:453–462. doi: 10.1056/NEJMoa0707035. - DOI - PubMed
    1. Tokunaga M., Ohyama S., Hiki N., Fukunaga T., Aikou S., Yamaguchi T. Can Superextended Lymph Node Dissection Be Justified for Gastric Cancer with Pathologically Positive Para-Aortic Lymph Nodes? Ann. Surg. Oncol. 2010;17:2031–2036. doi: 10.1245/s10434-010-0969-4. - DOI - PubMed

LinkOut - more resources